What is Leerink Partnrs’ Estimate for NAMS Q4 Earnings?

NewAmsterdam Pharma (NASDAQ:NAMS) – Investment analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a research note issued on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings per share of ($0.35) for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s FY2028 earnings at $0.42 EPS.

Several other equities research analysts have also recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Scotiabank upped their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $36.20.

NewAmsterdam Pharma Trading Down 1.7 %

NASDAQ NAMS opened at $25.46 on Thursday. The stock has a 50 day moving average price of $21.16 and a 200-day moving average price of $18.90. NewAmsterdam Pharma has a one year low of $10.29 and a one year high of $27.29.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $25.39, for a total value of $4,215,019.29. Following the completion of the sale, the insider now owns 11,150,461 shares of the company’s stock, valued at $283,110,204.79. The trade was a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 252,814 shares of company stock valued at $5,970,327 in the last three months. Company insiders own 19.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NAMS. Frazier Life Sciences Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after purchasing an additional 628,251 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after buying an additional 520,772 shares during the period. Decheng Capital LLC bought a new stake in NewAmsterdam Pharma during the 2nd quarter valued at $7,684,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of NewAmsterdam Pharma by 1,231.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after acquiring an additional 221,305 shares during the period. Finally, Millennium Management LLC raised its position in shares of NewAmsterdam Pharma by 23.0% in the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after acquiring an additional 217,902 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.